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THE PAST --OUT OF THE BOX 
In 1981, acquired immunodeficiency was proposed 
denominator of a newly defined syndrome of diseases 
that were on the rise in promiscuous male homosexuals 
and intravenous drug users (1). The reference to 
acquired immunodeficiency syndrome (AIDS) as a new 
disease (2,3), instead of a new syndrome composed of 
known diseases, inspired a search for a single new 
pathogen (2). In 1983 Montaigner and coworkers (4) 
suggested that pathogen to be lymphadenopathy-
associated virus [now termed human immunodeficiency 
virus(HIV)] and Gallo et al. (5) believed human T-cell 
leukemia virus (HTLV) infection to be the cause of AIDS. 
In April 1984 the US Secretary of Health and Human 
Services announced that HIV was the cause of AIDS, and 
an antibody test for HIV, termed the “AIDS test”, was 
registered as a patent by Gallo and collaborators (6,7). 
This happened even before any American study on HIV 
had been published (6), and has given rise to an HIV/AIDS 
denialism movement since. David Rasnick, an US AIDS 
nonconformist, and his colleagues University of California 
biologist Peter Duesberg and Charles Gechekter, were 
the loudest proponents of the theory that HIV could not 
be the cause of AIDS (8,9), and that AIDS was not an 
infectious disease at all. On the contrary, they postulated 
that recreational drugs, such as nitrate inhalants, 
antivirals such as zidovudine (AZT), and immune 
hyperstimulation were the exact causes (8). They were 
supported by Kary Mullis, who was Nobel prize laureate 
for chemistry for the discovery of the polymerase chain 
reaction (PCR) technique, sharing his own skepticism 
based on the inability to find a single widely-accepted 
scientific citation for the statement that HIV is the 
probable cause of AIDS. Moreover, there was not any 
clear evidence supporting sexual transitiveness of AIDS. 
“Modern science is based on the ability to demonstrate 
facts to the audience, no matter how skeptical those 
facts sound” he said. 
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In particular, Duesberg argued that HIV did not fulfill 
Koch’s postulates for identifying the causes of infectious 
diseases. In 1884 Robert Koch, discoverer of the anthrax 
bacillus, presented a group of conditions, termed Koch’s 
postulates for identifying the causes of infectious 
diseases. We present them herein in a very concise form, 
with Dusberg’s (counter) arguments: 
1) The agent occurs in each case of disease and in the 
amount sufficient to cause pathological effects. 
According to Duesberg, HIV violated this first postulate 
since free virus could not be documented in T 
lymphocytes of the peripheral blood of most people with 
AIDS. However, the HIV--T-cell specificity has lost ground 
since then, as HIV can often be detectable only in 
monocytes (10). Another tenet holding the case against 
HIV was that avirus that could be found in only 1 in 400 
peripheral blood lymphocytes could not possibly 
engender immunodeficiency. This, of course, contradicts 
the fact that blood, while being the easiest tissue to 
sample, is not the only one infected by HIV, so that we 
know nowadays that during the latent phase virus is 
filtered and trapped by dendritic cells of peripheral 
lymphoid tissue. Nowadays, the epidemiological 
concordance of HIV exposure and AIDS has been clearly 
shown in a number of different studies that document 
the presence of HIV or HIV antibodies in over 95% of 
AIDS patients (11–21). Moreover, Duesberg declared that 
AIDS could not have an infectious etiology because 
“viruses and bacteria work fast or never”. Here, he was 
mixing up viral replication at the cellular level with 
disease in the infected individuals. By his logic, 
treponema does not cause tertiary syphilis; hepatitis B 
virus does not cause chronic liver disease, and so on. 
2) The agent can be isolated and propagated outside the 
host. 
In the 1980s, HIV isolation, although possible in up to 
80% of AIDS cases, was technically very difficult. 
Nowadays, multiple HIV isolates are cultured, and HIV 
has been cultivated in fresh human T lymphocytes and 
macrophages. It is true that virus isolation is sometimes 
not successful, but the presence of HIV can be 
demonstrated by PCR amplification even of low 
abundance HIV genomes in most AIDS patients. Duesberg 
moreover believed that viruses do not cause disease 
after specific neutralizing antibodies appear in the blood. 
Therefore, HIV could not cause AIDS. In fact, the 
persistence of antibody’s titers for over a decade in AIDS 
patients is most likely explained by the continued 
stimulation of the humoral (antibody producing) immune 
system by low levels of sequestered virus. If not, 
antibody titer would drop off, as it does for other 
diseases when the pathogen is cleared. 
3) The transfer of the agent to an uninfected host leads 
to disease. 
Duesberg denied Koch’s third postulate stating that all 
attempts to cause AIDS in chimpanzees had been 
unsuccessful, even after they have been antibody-
positive for 4 to 5 years. The postulate of transmission 
pathogenesis cannot be fulfilled by epidemiological data, 
but instead is a requirement for direct empirical 
evidence. Ethical reasons preclude experimental 
transmission to uninfected human patients (except of 
Duesberg, who said to be considering the to imitate Max 
von Pettenkofer, who drank a Vibrio cholerae culture), 
making verification difficult. Therefore, this has been the 
most controversial Koch’s postulate with respect to HIV 
and AIDS. 
Epidemiology has been proposed as adequate to identify 
causative agents, particularly in human diseases where 
Koch’s postulates are difficult to meet, as in the case of 
HIV. The evidence that HIV causes AIDS is 
epidemiological and virological, not molecular. In every 
country and city where AIDS has appeared, HIV infection 
preceded it just by a few years; in every social group at 
risk of AIDS, HIV has preceded the disease. 
 
THE PRESENT -- OUT OF THE EYE 
AIDS/HIV Retinopathy 
Even with the eye being among the most common sites 
of involvement (22–27), this HIV/AIDS denialism 
movement surprisingly bypassed the ophthalmic 
community. 
Retinopathy is common and is generally classified as 
either noninfectious (AIDS-associated micro- and 
macrovasculopathy; HIV-associated neuroretinal 
disorder) or infectious (28–30). 
Microvasculopathy is described as the most common 
ocular manifestation of AIDS (31). Clinical findings may 
be recognized in the conjunctiva, retina, and optic disk. 
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Retinal microvasculopathy is clinically known for cotton-
wool spots located in the posterior pole. Micro-
aneurysms are clinically not often obvious, but 
occasionally may be visible on the fluorescein angiogram. 
Cotton-wool spots have rounded borders, are not 
associated with significant amounts of adjacent 
hemorrhage (although scattered dot and blot 
hemorrhages may be present), and do not enlarge. The 
optic disk may develop pallor consequent to 
microvascular occlusion. Most microvasculopathy 
patients are asymptomatic (32). Histopathologically, 
findings of AIDS microvasculopathy bear a resemblance 
to those of diabetic retinopathy. Retinal vascular 
abnormalities include necrosis of pericytes, endothelial 
cell swelling, and thickened basement membranes. The 
pathophysiology of the vascular injury is controversial. 
Hypotheses include immunoglobulin deposition, 
endothelial cell infection by HIV, and hyperviscosity. 
Retinal macrovasculopathy, accompanied by large vessel 
occlusions, including noninfectious branch retinal artery 
occlusions and central and branch retinal vein occlusions 
(31) are extremely unusual. 
HIV-associated neuroretinal disorder is characterized by 
subtle vision abnormalities –visual field loss, reduced 
contrast sensitivity, altered color vision, and diminished 
visual acuity—all in the absence of ocular opportunistic 
infections (33–34). The proportion of patients with visual 
functional abnormalities among HIV-positive individuals 
appears to be higher than that of the general population, 
even in the absence of any apparent ocular pathology or 
severe immunosuppression. Belonging to social sub-
cultural minorities, history of intravenous drug use, lower 
Karnofsky score, anemia, and lack of private health 
insurance, all bring about a significantly increased risk of 
visual field loss. Kalyani et al have described a structural 
basis for this disease, correlating worsening contrast 
sensitivity and color vision with temporal thinning of the 
peripapillary retinal nerve fiber layer (RNFL) using 
spectral domain optical coherence tomography (SD-OCT) 
in HIV-positive patients without history of ocular 
disease.The RNFL and the unmyelinated prelaminar optic 
nerve have high concentrations of mitochondria, 
required for the energy intensive maintenance of axonal 
membrane potentials and axonal transport. There is 
evidence suggesting that HIV infection itself or its 
treatment (specifically, treatment with certain 
nucleoside reverse transcriptase inhibitors) is toxic to 
mitochondrial function, resulting in skeletal myopathies, 
peripheral neuropathies, insulin resistance, and life-
threatening lactic acidosis. They suggest that the smaller 
caliber axons comprising the maculopapillary bundle are 
more susceptible to mitochondrial toxicity and resultant 
axonal loss, mediated by antiretroviral therapy, leading 
to the visual functional decline associated with 
neuroretinal disorder. 
Posterior segment opportunistic infections develop 
either in a pattern of a necrotizing retinitis or a unifocal 
or multifocal choroiditis. Retinitis is more prevalent than 
choroiditis. Except toxoplasmosis, cryptococcus, and 
syphilis, which may present as either retinitis or 
choroiditis, opportunistic agents are included in a 
differential diagnosis specific to the clinical presentation 
of the infection. Necrotizing retinitis may be clinically 
further subdivided based upon the extent of associated 
ocular inflammation. Retinitis in inflamed eyes usually 
occurs in patients with higher CD4+ counts and is more 
commonly due to acute retinal necrosis, toxoplasmosis, 
syphilis, or late stages of Cryptococcus spp. infection. 
Retinitis in quiet eyes occurs in patients with lower CD4+ 
counts and is more commonly due to cytomegalovirus 
(CMV) and progressive outer retinal necrosis. 
Highly Active AntiRetroviral Therapy (HAART) 
When two or more nucleoside reverse transcriptase 
inhibitors are combined with either a protease or a non-
nucleoside reverse transcriptase inhibitors, HIV 
replication is suppressed more efficiently than with any 
drug class alone. The combination regimen is termed 
highly active antiretroviral therapy (HAART) and its 
potency is related to the lower likelihood of the 
development of viral resistance to antiretrovirals (35, 
36). HIV protease is a crucial proteolytic enzyme involved 
in the cleavage of viral polyproteins and production of 
functional protein products during the late stages of HIV 
replication. Protease inhibitors lay off HIV replication by 
blocking the cleavage of the Gag-Pol polypeptide through 
occupation of the active site of HIV protease, leaving so 
immature virus, incapable of infecting new CD4 cells (1). 
In 1996 protease inhibitors were approved for treatment 
of patients with HIV and currently include saquinavir 
(Fortovase), saquinavir mesylate (Invirase), ritonavir 
(Norvir), amprenavir (Agenerase), lopinavir (Kaletra), 
indinavir sulfate (Crixivan), nelfinavir mesylate (Viracept), 
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and atazanavir sulfate (Reyataz). Before protease 
inhibitors were introduced, the mainstays of HIV therapy 
were the nucleoside and non-nucleoside reverse 
transcriptase inhibitors, both of which suppress HIV 
replication by inhibiting the RNA directed DNA 
polymerase, reverse transcriptase (37). Nucleoside 
reverse transcriptase inhibitors are nucleoside analogs 
and include zidovudine (Retrovir), stavudine (Zerit), 
lamivudine (Epivir), abacavir (Ziagen), didanosine (Videx), 
zalcitabine (Hivid), and emtricitabine (Emtriva). Non-
nucleoside reverse transcriptase inhibitors include 
efavirenz (Sustiva), nevirapine (Viramune), and 
delavirdine mesylate (Rescriptor). In patients who 
respond to HAART, a rise in CD4+ counts and sustained 
suppression of HIV replication may occur (38). Recovery 
of the immune system with HAART results from 
increased absolute CD4+ cell counts, first by an increase 
in memory T cells and later by renewed production of 
naïve CD4+ T cells (39). If suppression of HIV replication 
lasts for long enough, lymphoproliferative responses may 
be restored even in patients with previous severe 
immunodeficiency (40),  restoring natural protection 
against many opportunistic infections (41). 
Is HIV the cause of AIDS manifestations in the eye? 
If Duesberg were an ophthalmologist, he would argue 
that manifestations of HIV infection in the eye are 
different from AIDS manifestations. 
Logically, posterior segment opportunistic infections are 
strictly correlated with the AIDS-associated lymphopenia 
rather than HIV infection itself. In 1996, the introduction 
of HAART rapidly and dramatically shifted the trajectory 
of the HIV/AIDS epidemic, increasing life expectancy and 
decreasing the incidence of opportunistic infections and 
malignancies. (42, 43). Prior to the HAART era, the 
lifetime incidence of CMV retinitis in HIV/AIDS patients 
approached 30%; the rate of new cases has dropped 80–
90% with HAART(44–49). The importance of HAART and 
its resultant effect on CD4+ count in controlling 
progression or reactivation of CMV retinitis cannot be 
overemphasized; in fact, in patients whose immune 
system is reconstituted (CD4+ count ≥ 100 cells/mL at 
two or more consecutive visits at least 6 months apart), 
HAART is probably more important than targeted anti-
CMV treatment. 
However, other ocular opportunistic infections, such as 
ocular syphilis, appear to be unaffected (50). HAART has 
a less dramatic effect on the epidemiological and clinical 
aspects of the ocular syphilis in HIV-infected patients 
compared to that observed with CMV retinitis. In many 
respects, ocular syphilis continues to be an 
undiscriminating disease, irrespective of CD4+ count and 
immunodeficiency (51–55). Furthermore, HAART has no 
effect at all on the incidence of HIV micro- and 
macrovasculopathies, which, Duesberg would say, are a 
consequence of HIV infection of the retinal endothelial 
cells and pericytes rather than a part of the AIDS 
spectrum. Duesberg’s hypothesis that AIDS may be 
caused by intravenous drug use and antiretroviral 
therapy seems to have at least a part of truth when it 
comes to the eye, since the retina is among the most 
metabolically active tissues, making it a prime target for 
unwanted side effects of chemotherapeutic agents. Since 
the introduction of HAART, for example, a new 
pathological entity termed HIV-associated neuroretinal 
disorder has been detected in the eye. These subtle 
vision abnormalities have been associated with minority 
status and history of intravenous drug use, but at the 
same time it has been demonstrated that antiretroviral 
therapy, which is toxic to mitochondrial function, 
damages the RNFL and the unmyelinated prelaminar 
optic nerve which have high concentrations of 
mitochondria. 
 
CONCLUSIONS 
Nowadays there is clearly no doubt that HIV, if not 
adequately controlled with antiretroviral therapy, is the 
cause of a severe lymphopenia which opens the door to 
a wide spectrum of opportunistic infections and tumors 
that constitute as a whole the spectrum of AIDS.  
However, Duesberg would surely have been very 
fascinated by the posterior segment manifestations of 
HIV infection in the eye. Some of these are caused 
directly by HIV damage to retinal vessels (and therefore 
should be referred as HIV-vasculopathy, instead of AIDS-
vasculopathy). Some are sequelae of HAART toxicity (a 
point to Duesberg).Finally, others have nothing to do 
with direct HIV infection but are caused by opportunistic 
infections which gain access to the eye when the T 
lymphocytes count drops (AIDS-related infectious 
retinitis). 
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